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http://dx.doi.org/10.1016/j.pedneo.2Juvenile myelomonocytic leukemia (JMML) is a rare hematologic malignancy in children. Its
presentations include anemia, thrombocytopenia, monocytosis, skin rash, marked hepatomeg-
aly, and/or splenomegaly. Fever and respiratory involvement are common. Here, we report a
case of a premature neonate with initial symptoms of respiratory distress. She gradually devel-
oped clinical manifestations of JMML that mimicked neonatal sepsis. Three weeks after birth,
JMML was diagnosed. This is the first reported case of JMML presenting in a premature infant in
Taiwan.
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Juvenile myelomonocytic leukemia (JMML) is a very rare
pediatric hematopoietic malignancy. The median age of
diagnosis is about 2 years old.1,2 Infants or children with
JMML clinically present with pallor, fever, infection, and
skin rash. Accompanying clinical findings include lymph-
adenopathy and hepato-splenomegaly. It has been defined
as a myelodysplastic/myeloproliferative neoplasm by theed by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Peripheral blood smear showed leukocytosis with
increased monocytes. Wright stain; magnification, 1000.
150 M.-L. Lee et alWorld Health Organization (WHO) classification in 2008 but
due to recent identification of novel gene mutations in
JMML, the diagnostic criteria of JMML were further modi-
fied in 2011.3,4 Although the diagnosis of JMML is facili-
tated, early diagnosis remains a challenge. This is a report
on a premature neonate with JMML.
2. Case Report
A female newborn was delivered at 35 weeks of gestation to
a 33-year-old female (gravida 4, para 2) in a tertiary
teaching hospital. The baby had a birth weight of 2730 g
and measured 44.5 cm in length. Her APGAR scores were 4
at 1 minute and 5 at 9 minutes. Because she presented with
mild respiratory distress, the baby was admitted.
On review of her prenatal history, thickened nuchal
translucency was noted at 17 weeks of gestational age,
although the prenatal cytogenetic study was normal.
However, multiple congenital abnormalities were found
after birth, including a boat-shaped head, ear anomaly with
bilateral low-set ears, high arch palate, micrognathia, short
neck, left simian crease, and edema over the bilateral
hands, feet and the labia major. A pediatric geneticist was
consulted, but no definite syndrome of chromosomal ab-
normality was suspected.
Complete blood count (CBC) on the 1st day of life
revealed a white blood cell (WBC) count or 22.8  109/L
(segments 40%, lymphocytes 30%, and monocytes 6%), he-
moglobin (HGB) 13.9 g/dL, and platelets (PLT) 253  109/L
(Table 1). The baby had progressive respiratory distress
with tachypnea on her 3rd day of life. Patent ductus arte-
riosus 0.35 cm with left to right shunt was found by ultra-
sonography and she received oral Ibuprofen twice.
However, fever, poor activity, cutis marmorata, hypoten-
sion, and bradycardia developed later. The baby was intu-
bated and provided ventilator support. Repeated
laboratory workup showed WBC 45.07  109/L, monocytes
36%, HGB 8.3 g/dL, PLT 232  109/L, and C-reactive protein
(CRP) <0.05 mg/dL.
On her 9th day of life, the baby still appeared pale
despite aggressive blood transfusion for severe anemia
(HGB 5.1 g/dL) and thrombocytopenia (PLT 86  109/L).
Peritoneal dialysis was initiated for acute renal failure.
Brain ultrasonography showed left intra-cerebral hemorr-Table 1 Complete blood counts of the patient.
Age* WBC (109/L) HGB (g/dL) PLT (109/L) D
BAND SEG LYM
1 22.8 13.9 253 0 40 30
7 45.1 8.3 232 2 33 17
15 15.3 11.0y 35 0 67 19
22 24.1 15.6y 76y 0 28 21
25 40.6 9.8 104y 0 45 27
33 39.7 8.9 32 0 58 11
46 23.7 13.3y 60y 0 82 8
BAND Z bands; BASO Z basophils; DC Z differential count; E
NRBC Z nucleated red blood cells; SEG Z segments.
* Age in days.
y Post-transfusion laboratory report within 3 days of transfusion.hage (3  4 cm). Meanwhile, aggressive supportive care and
empirical antibiotics were administered.
Her clinical condition remained poor but stable in the
following weeks. All viral studies, including virus serological
survey [i.e., toxoplasma, cytomegalovirus (CMV), herpes
simplex virus, human immunodeficiency virus EIA test,
Epstein-Barr virus (EBV)] and viral cultures were negative.
Successive bacterial cultures of blood, cerebral spinal fluid,
and ascites did not yield any bacteria.
Severe anemia and thrombocytopenia persisted, with
increased monocyte count to more than 10.0  109/L since
the 7th day of life. Marked hepato-splenomegaly developed
in the 3rd week. A peripheral blood smear showed 2%
erythroblasts with the presence of myeloid precursors
(Figure 1). Bone marrow aspiration revealed increased
granulopoiesis, markedly increased monocyte series to 20%,
no giant pro-erythroblasts with prominent intra-nuclear
inclusions, and no excess of blasts. (Figure 2). Cytoge-
netic study of bone marrow and Southern blotting of the
BCR/ABL fusion gene also had normal results. She had an
elevated serum vitamin B12 level (>2000 pg/mL) and post-
transfusion hemoglobin electrophoresis demonstrated 1.3%
HbF and 2.5% HbA2. Juvenile myelomonocytic leukemia
(JMML) was diagnosed.C (%) Monocytes (109/L) NRBC/100WBC (%)
MON EOS BASO
6 24 0 1.368 3
36 12 0 16.225
12 2 0 1.836 17
50 1 0 12.050 8
28 0 0 11.359 9
30 1 0 11.904 2
9 1 0 2.133 1
OS Z eosinophils; LYM Z lymphocytes; MON Z monocytes;
Figure 2 Bone marrow smear showed increased precursor
cells of myeloid and monocytes series, without any excess of
blasts. Wright stain; magnification, 1000.
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with upward gaze were noted. Brain magnetic resonance
imaging (MRI) revealed multiple intra-cranial hemor-
rhages with hydrocephalus. Despite emergency extra-
ventricular drainage, the baby’s condition further dete-
riorated. Her deranged hemogram also persisted. The
parents refused further transfusion and the baby died
after 58 days of life.
3. Discussion
Juvenile myelomonocytic leukemia (JMML) is a clonal he-
matopoietic disorder of childhood that has features of both
myeloproliferation (leukocytosis and monocytosis) and
myelodysplasia (anemia and thrombocytopenia).5
Pallor, fever, infection, skin rash, bleeding problems,
and cough are the most common presenting symptoms.1
Like most patients with JMML, the present case initially
presented with fever and signs of respiratory involvement.
However, severe neonatal infectious diseases, sepsis, and
JMML often present with a similar clinical picture. The
manifestations of several microbial infections, such as EBV,
CMV, human herpes virus-6, histoplasma, mycobacteria,
and toxoplasma, may mimic JMML.6 Parvovirus B19Table 2 Current diagnostic criteria for juvenile myelomonocyti
Category 1 (All of the following) Category 2 (At least on
the following)
1) Absence of the BCR/ABL1
fusion gene
2) >1  109/L circulating
monocytes
3) <20% blasts in the bone marrow
4) Splenomegaly
1) Somatic mutation in
2) Clinical diagnosis of
gene mutation
3) Monosomy 7
Patients who have Category 2 lesions need to meet the Category 1 crit
lesions must meet the Category 1 and 3 criteria.
* Modified from [4].infection can also reportedly cause symptoms and signs
mimicking JMML in newborns.7 Thus, infectious diseases
should be carefully excluded before the diagnosis of JMML
is made.
A variety of infectious organisms were thoroughly
investigated in this current case, and all yielded negative
results. Multiple viral cultures from all sterile body fluids
yielded nothing. Due to the unavailability of PCR assay or
IgM of parvovirus B19 in the hospital, these were not
studied in this patient. However, pathognomonic bone
marrow findings of parvovirus B19 infection, including giant
pro-erythroblasts with prominent intra-nuclear inclusions
and cytoplasmic vacuolations, were not identified. More-
over, her poor but stationary clinical condition, deranged
hemogram regardless of antibiotic use, and persistently low
CRP levels made the diagnosis of infection-related myelo-
proliferative disorder less likely.
The diagnostic criteria for JMML include three categories
(Table 2).3,4 The baby met all four features within Category
1 (absence of BCR/ABL fusion gene, peripheral blood
monocytosis greater than 1  109/L, <20% blasts in the
bone marrow, and splenomegaly) and two features in
Category 3 (WBC count greater than 10  109/L and circu-
lating myeloid precursors). On these bases, the diagnosis of
JMML was made. In the absence of features within Category
3, genetic mutation analysis (Category 2) for NRAS, KRAS,
PTPN11, NF1, and CBL provided strong aid in diagnosing
JMML.8
Juvenile myelomonocytic leukemia usually occurs in
young children. The median interval between the onset of
symptoms and diagnosis of JMML is 1.9 months (range, 0e23
months) in the study of Niemeyer et al.1 The median age of
diagnosis is about 2 years old.1,2 Chang et al reported 16
patients with JMML in Taiwan with a median age at diag-
nosis of 2.5 years old.9 The youngest patient in their study
was 9 months old.9 Chen et al also reported a Taiwanese
male infant with JMML diagnosed at 6 months old who did
not survive the next 2 months.10 Most of the infants had
fever as their first symptom and eventually developed
marked hepato-splenomegaly with persistent monocytosis.
Only two cases of JMML diagnosed in premature infants
have been reported in literature.11,12 Their presentations
are similar to those of the current case report. The two
previous cases were born at a gestational age of 30 and 34
weeks, respectively. Their refractory anemia and throm-
bocytopenia were not present until 18 days and 1 week ofc leukemia.*
e of Category 3 (Two of the following if no
Category 2 criteria are met)
RAS or PTPN11
NF1 or NF1
1) WBC count >(10  109/L)
2) Circulating myeloid precursors
3) Increased Hb F for age
4) Clonal cytogenetic abnormality
excluding monosomy 7
5) GM-CSF hypersensitivity
eria but not the Category 3 criteria. Patients who have Category 3
152 M.-L. Lee et alage, respectively. Both cases were proven to be Noonan
syndrome (NS)-related JMML.
Noonan syndrome is an autosomal dominant disease
characterized by facial dysmorphology, short stature, and
congenital heart defects.13 Facial dysmorphology includes a
triangular-shaped face, hypertelorism, down-slanting eyes,
and strabismus. Children with NS may exhibit pectus car-
inatum or excavatum, lymphedema, hypotonia, and seizure
disorder. They are reported to display a self-resolving
myeloproliferative disorder in infancy that resembles
JMML.4 Tartaglia et al identified germline mutations in
PTPN11 as causative in approximately 50% of children with
NS.14 Based on typical clinical features and/or additional
genetic test, the diagnosis of Noonan syndrome can be
made. Mutations in PTPN11 are also identified as somatic
lesions in de novo, nonsyndromic JMML and it has a fre-
quency of up to 35% of patients in some series.4
Due to the co-existence of multiple anomalies and JMML,
NS was suspected in this case patient. However, no typical
features of NS were identified after detailed examinations
by the geneticist. Unfortunately, genetic tests such as
PTPN11mutation were not arranged due to parental refusal.
To date, this is the first case of JMML presenting in a
premature infant in Taiwan. Quick infectious survey and
early recognition of noninfectious etiologies in a patient
with clinical presentations mimicking neonatal sepsis is
crucial for the early diagnosis of JMML in premature
babies.
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